Advertisement


Daniel Kates-Harbeck, MD Candidate, and Nadia Harbeck, MD, PhD, on Personalizing Breast Cancer Management With AI: Novel Approach to Predicting Outcomes

2023 SABCS

Advertisement

Nadia Harbeck, MD, PhD, of LMU University Hospital and Ludwig Maximilian University of Munich, and Daniel Kates-Harbeck, of the West German Study Group and an MD Candidate at Ludwig Maximilian University of Munich, discuss a learning-based neural network developed by Mr. Kates-Harbeck to predict treatment outcomes in early breast cancer as well as potentially other tumor types (Abstract PO 04 1-10).



Related Videos

Breast Cancer

Oleg Gluz, MD, on Response to Endocrine Therapy: Findings From the ADAPTcycle Trial

Oleg Gluz, MD, of the West German Study Group and Breast Center Niederrhein, discusses the impact of age and ovarian function suppression in response to preoperative endocrine treatment for both pre- and postmenopausal patients with early-stage breast cancer. He describes ways in which the outcome data of the ADAPTcycle study might influence clinical decisions (Abstract LBO1-05).

Breast Cancer

Aditya Bardia, MD, MPH, on Early-Stage, High-Risk Breast Cancer: New Data on Pembrolizumab Plus Chemotherapy

Aditya Bardia, MD, MPH, of Massachusetts General Hospital Cancer Center, discusses phase III findings from the KEYNOTE-756 study, which showed that adding pembrolizumab to chemotherapy increases the pathologic complete response rate and lowers the residual cancer burden in patients with early-stage, high-risk ER-positive or HER2-negative breast cancer (Abstract GS01-02).

Breast Cancer

Hope S. Rugo, MD, on Advanced Breast Cancer: Patient-Reported Outcomes From the CAPItello-291 Trial

Hope S. Rugo, MD, of the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses patient-reported outcomes from the phase III CAPItello-291 study; the trial centered on adding capivasertib to fulvestrant in patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer. Patients treated with capivasertib and fulvestrant reported maintained health-related quality of life longer than those treated with placebo and fulvestrant (Abstract PS02-02).

Aditya Bardia, MD, MPH, on HR-Positive, HER2-Negative Advanced Breast Cancer: New Findings on Datopotamab Deruxtecan vs Chemotherapy

Aditya Bardia, MD, MPH, of Massachusetts General Hospital Cancer Center, discusses updated phase III results from the TROPION-Breast01 study. The data showed an improvement in progression-free survival with datopotamab deruxtecan compared with investigator’s choice of chemotherapy across all subgroups of patients with inoperable or metastatic hormone receptor–positive, HER2-negative breast cancer who have received one to two prior lines of chemotherapy (Abstract GS02-01).

Breast Cancer

Sara A. Hurvitz, MD, on Metastatic Breast Cancer: New Data on Tucatinib and Trastuzumab Emtansine

Sara A. Hurvitz, MD, of Fred Hutchinson Cancer Research Center, University of Washington, discusses phase III findings of the HER2CLIMB-02 study, which showed the combination of tucatinib and trastuzumab emtansine improved progression-free survival in patients with previously treated, HER2-positive, locally advanced or metastatic breast cancer (including those with brain metastases) (Abstract GS01-10).

Advertisement

Advertisement




Advertisement